학술논문
Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis
Document Type
Article
Author
Source
Farmacia Hospitalaria; 20240101, Issue: Preprints
Subject
Language
ISSN
11306343
Abstract
Topical rapamycin is the pharmacological treatment of choice for facial angiofibromas in rare tuberous sclerosis disease. A new, more advanced, and complex formula was developed in our pharmacy service: rapamycin 0.4% liposomal formulation, with better organoleptic characteristics and a more favorable release profile of the active ingredient.